2023 Annual Conference   |  April 12-14, 2023   |  Salt Lake City, Utah, USA

Call for Abstracts

Posters give authors and conference participants the opportunity to connect with each other and build upon the foundation of shared knowledge and collaboration.

Eligibility

Abstracts are open to all professionals in the industry and medical fields, consistent with the mission of CCF “to find a cure and improve the quality of life for cholangiocarcinoma patients.”

Benefits for Poster Presenters

  • Abstracts will be posted on the CCF website.
  • Receive recognition awards.
  • Discuss your work with researchers, clinicians, policymakers, industry representatives, patients, and others from around the world who are invested in the field of cholangiocarcinoma.
  • Sharpen your presentation skills and abilities.
  • Six abstracts with a basic, translational and clinical research focus will be featured for rapid-fire oral presentations. Those selected will receive a travel stipend.

Abstract Guidelines

  • Abstracts must be submitted online via the abstract submission form. No fax copies, disks, or email submissions will be accepted.
  • Poster abstract submissions must be in English.
  • Abstracts must be properly formatted and organized into five sections with the following headers:
    • Title
    • Background & Objectives
    • Method
    • Results
    • Conclusion
    • Relevant charts and/or diagrams are permitted and will not be counted in the word limit
  • Abstract text must not include citations.
  • Abstracts must not refer to proprietary names.
  • Institution names should not be included in the title or body of the abstract to ensure blinded and non-biased review.
  • In cases of previously reported data, authors are responsible for ensuring copyright compliance.

Participant Disclosure Information

Authors must disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in an educational presentation, as well as any discussion of unlabeled or unapproved use of drugs or devices.

Selection Criteria

  • Submissions will be reviewed and rated by members of the Abstract Review Committee who have clinical and research expertise in the field of cholangiocarcinoma.
  • Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.

Submission Deadline

  • Abstract submission deadline: Monday, January 9th, 2023, 11:59 p.m. (EST).
  • Abstract review process: Monday, January 16th, 2022, until, Monday, February 13th, 2023.
  • Abstract notifications sent via email to first authors: Friday, February 17th, 2023.
  • Abstract change/withdrawal deadline: Monday, February 20th, 2023, 11:59 p.m. (EST).

Contact

Kristine Hamilton, kristine.hamilton@cholangiocarcinoma.org

Day
Hour
Minute
Second